$Moderna, Inc.(MRNA)$ Is A Stock To Buy?1. Attention: vaccine sales potential ahead$Moderna, Inc.(MRNA)$ already has signed contracts worth $19.2 billion in product sales this year. Along with rival Pfizer, it's a leader in the U.S. coronavirus vaccine market. Each company is supplying the U.S. with 300 million doses. But product sales probably haven't peaked this year. CEO Stephane Bancel recently predicted need would be greater next year. A variety of elements will contribute to that. 2. Another product on the horizonThe one that catches my eye right now is its vaccine candidate for cytomegalovirus (CMV). That's because it's farthest along in the pipeline -- so it could re